Complicated intra-abdominal infections (cIAIs) remain a substantial challenge in US hospitals. Those suffering from a cIAI often require complex management that includes source control and proper antimicrobial coverage \[[@CIT0001]\]. Because of the severity of illness associated with cIAI and the need for complex care, these patients face a considerable risk of death \[[@CIT0002]\]. The potential for mortality increases further when the patient is exposed to inappropriate empiric therapy (IET). In the current era of escalating rates of antimicrobial resistance, the potential for IET is significant \[[@CIT0003]\].

Conversely, overuse of broad-spectrum agents where they are not necessary to cover potential pathogens drives up rates of resistance. This phenomenon has been particularly evident in the case of carbapenems, which are often recommended as broad-spectrum empiric treatment in high-risk cIAI patients. In part, concern about the prevalence of extended-spectrum beta-lactamase (ESBL)--producing Enterobacteriaceae and *Pseudomonas aeruginosa* has contributed to greater use of carbapenems in cIAI. However, because of broader reliance on carbapenems, once considered a "last-resort" antibiotic for those with life-threatening infections, the class is losing its in vitro potency, and now resistance to carbapenems is often seen in *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and Enterobacteriaceae \[[@CIT0019]\].

Balancing the need for sufficiently broad-spectrum agents with the need to curtail resistance is a challenge for the bedside clinician. Often treatment decisions derive from information generalized at the level of the pathogen, failing to consider its prevalence in the specific disease state necessary to make treatment choices. Additionally, to make recommendations regarding appropriate carbapenem use and to benchmark rates of compliance with formal guideline recommendations, one must understand current practices. To address these issues, we examined the microbiology and outcomes of patients in the United States hospitalized with cIAI in the context of their exposure to empiric treatment with a carbapenem (ECT).

METHODS {#s1}
=======

We performed a multicenter retrospective cohort study of hospitalized patients with International Classification of Diseases (ICD)-9-CM codes (or their ICD-10 equivalents after October 2015) indicating cIAI (the details of the algorithm are presented in the [Supplementary Data](#sup11 sup12){ref-type="supplementary-material"}) \[[@CIT0018]\]. In addition, we required that there be evidence of antibiotic treatment that began on the day culture was obtained and was continued for at least 3 consecutive days, or until discharge \[[@CIT0022]\].

Because this study used already existing fully de-identified data, it was exempt from institutional review board review under 45 CFR 46.101(b)4 \[[@CIT0025]\].

Study Population {#s2}
----------------

Patients were included if they were adults (aged ≥18 years) whose hospitalization of 2 days or longer included a diagnosis of cIAI. We required that an abdominal and/or blood culture drawn during or within 48 hours after laparotomy/laparoscopy be positive for a causative organism (list below), as well as evidence of antibiotic treatment on the day of surgery or index culture that continued for ≥3 consecutive days. Patients not meeting these criteria were excluded from the cohort. Additionally, we excluded patients with a concurrent urinary tract infection diagnosis at any time during the hospitalization in order to minimize the risk of source misattribution of positive blood cultures. Finally, we excluded patients transferred from another acute care facility, as our primary interest focused on the empiric treatment period.

Data Source {#s3}
-----------

The data for the study were obtained from the Premier database, an electronic laboratory, pharmacy, and billing data repository, for the years 2013 through 2017. The database represents \~15% of all hospitalizations nationwide. For further description of the database, see the [Supplementary Data](#sup12){ref-type="supplementary-material"}.

Baseline Measures {#s4}
-----------------

cIAI was classified as community-onset (CO) if present on admission or if the index culture was obtained within the first 2 hospital days. CO cIAI was further classified as health care--associated (HCA) if 1 or more of the following risk factors was present: (1) prior hospitalization within 90 days of the index hospitalization, (2) hemodialysis, (3) admission from a long-term care facility, and (4) immune suppression. All other CO infections were defined as community-acquired (CA). All cIAIs occurring on or after hospital day 3 were considered hospital-onset (HO). In addition to infection classification, patient factors examined included history of exposure to antibiotics within 90 days before the index admission, exposure to antibiotics during the index hospitalization before the onset of cIAI if HO, demographic variables, and comorbid conditions. We computed the Charlson comorbidity score as a measure of the burden of chronic illness, whereas ICU admission, need for mechanical ventilation, presence of severe sepsis or septic shock, and use of dialysis and/or vasopressors at baseline (day of surgery/index culture) served as markers for acute disease severity. Organisms and their susceptibilities were identified, and empiric antibiotic treatment was considered appropriate if the patient received a regimen that covered the corresponding organism within 2 days of the culture being obtained. The prevalence of carbapenem as empiric therapy in each institution was derived as a baseline hospital-level variable. We also explored hospital structural characteristics (eg, size, teaching status, urbanicity) and processes of care (eg, choices of antimicrobials), as they impacted patient outcomes.

Microbiology and Antimicrobial Treatment Variables and Definitions {#s5}
------------------------------------------------------------------

### Organisms of Interest {#s6}

To be included, a patient had to grow out at least 1 qualifying organism in the abdominal fluid or blood, including any of the gram-negative organisms listed below. The first culture growing out one of the organisms of interest served as the index culture.

Gram-negative organisms of particular interest were *Pseudomonas aeruginosa, Acinetobacter baumannii*, *Stenotrophomonas maltophilia,* and Enterobacteriaceae. The [Supplementary Data](#sup11 sup12){ref-type="supplementary-material"} lists organisms included as Enterobacteriaceae.

The prevalence of the following frequent cIAI pathogens was also examined: *Enterococcus* spp., *Staphylococcus aureus* (including methicillin-resistant *S. aureus* \[MRSA\]), *Bacteroides fragilis*, and *Candida* spp. In addition, we noted if a polymicrobial infection was present.

Definitions of carbapenem resistance (CR), third-generation cephalosporin resistance (C3R), and inappropriate empiric therapy (IET) can be found in the [Supplementary Data](#sup11 sup12){ref-type="supplementary-material"}.

Outcomes {#s7}
--------

The primary outcome of interest was hospital mortality as it relates to ECT. Secondary outcomes included hospital length of stay (LOS; in days, total and post--infection onset for all and for survivors only), total costs and total post--infection onset costs, and 30-day readmission rates among survivors. We further explored several additional outcomes associated with ECT as compared with other regimens (non-ECT):

1.  Development of *Clostridioides difficileC. difficile* (ICD-9-CM 008.45) not principal diagnosis or present on admission*C. difficile* included as secondary diagnosis*C. difficile* treatment (oral metronidazole OR oral vancomycin OR fidaxomicin) started on either: i. Hospital day 3 or later, if index surgery/culture was on hospital day 1--2, orii. On day of surgery or later, if index surgery/culture was on hospital day 3 or later

2.  Development of acute kidney injury (AKI) or AKI requiring dialysis (AKI-D), as identified by a previously published algorithm, on the day of index surgery/culture or later \[[@CIT0026]\]

3.  Clinical deterioration, defined as institution of vasopressors and/or mechanical ventilation (MV) within 3 days after the index surgery/culture if not present on index day

4.  Treatment failure Recurrence of infection, defined as re-initiation of antimicrobial treatment with the same or broader-spectrum regimen after a treatment-free period of ≥3 daysTreatment escalation, defined as addition of an antimicrobial or switch to a new antimicrobial with a broader spectrum of coverage within 7 days after the index surgery \[[@CIT0027]\]Need for a repeat laparotomy/laparoscopy or percutaneous drainage within 7 days after the index surgery \[[@CIT0027]\]

Statistical Analyses {#s8}
--------------------

All demographics, comorbidities, hospital characteristics and processes, and hospital outcomes were compared between the ECT and non-ECT groups using standard summary statistics. Continuous variables were reported as means with standard deviations and as medians with 25th and 75th percentiles (interquartile range). Differences between mean values were tested via the Student *t* test, whereas those between medians were examined using the Mann-Whitney *U* test. Categorical data were summarized as counts and frequencies, and the chi-square test or Fisher exact test for cell counts \<4 was used to examine between-group differences. Inference tests with a *P* value \<.05 were considered statistically significant.

We developed multilevel (hierarchical) mixed-effects logistic regression models with hospitals treated as random effects to examine the contribution of empiric carbapenem treatment to clinical deterioration, *C. difficile* development, AKI and AKI-D onset, mortality, and 30-day readmissions. A competing risk regression model (with mortality as the competing risk) was used to model treatment failure. The impact of empiric carbapenem treatment on costs (both total and post--infection onset) and hospital LOS (both total and post--infection onset) was examined using multilevel mixed-effects generalized linear models with a logarithmic link function and a gamma distribution (or a normal distribution for postinfection LOS, as some values equaled 0). In all models, we examined the covariates present from the start of hospitalization through the day of the onset of the index infection.

All statistical analyses were done with Stata/MP 15.1 for Windows (StataCorp, LLC, College Station, TX, USA).

RESULTS {#s9}
=======

Among 321 317 patients with cIAI, 4453 (1.4%) were culture-positive, met all the inclusion criteria, and were analyzed in the cohort ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The most common reason for exclusion was the absence of a positive culture (81.1%).

A little over one-third of the cultures came from an abdominal source only (n = 1686), with an additional 545 (12.2%%) from blood only, and another 2222 (49.9%) from both. Although the majority of all cIAIs had gram-negative (GN) organisms, a substantial minority had a gram-positive (GP) pathogen (40.0%), among which *Enterococcus* sp. was the most frequent (60.2%) ([Table 1](#T1){ref-type="table"}). A total of 4032 GN organisms were isolated from 3771 patients, with *E. coli* being the most common (56.7%), with a C3R prevalence of 4.9% and CR of 0.3%. Overall, C3R and CR prevalence was 7.6% and 2.2%, respectively, among all GN isolates, and *A. baumannii* was most likely to be C3R and CR (21.4% for each) ([Table 1](#T1){ref-type="table"}). Approximately one-third of the cohort suffered from polymicrobial infections (n = 1512), with the rest growing a single organism. Among those with a polymicrobial infection, 1100 (72.8%) were mixed GN and GP.

###### 

Microbiology of cIAI^a^

                               Patients With a GN Isolate (n = 3771)                         
  ---------------------------- ----------------------------------------- ---- -------- ----- --------
  Overall                      3286                                      84   2.23%    288   7.64%
  Organism                                                                                   
  * Klebsiella pneumoniae*     655                                       12   1.55%    19    2.45%
  * Proteus mirabilis*         103                                       7    5.98%    5     4.27%
  * Escherichia coli*          2285                                      7    0.27%    129   4.92%
  * Enterobacter cloacae*      191                                       9    3.96%    46    20.26%
  * Providencia* spp.          9                                         1    10.00%   0     0.00%
  * Serratia marcescens*       19                                        0    0.00%    1     4.17%
  * Morganella morganii*       44                                        4    9.09%    5     11.36%
  * Enterobacter aerogenes*    52                                        4    6.67%    12    20.00%
  * Proteus* other             18                                        2    8.70%    2     8.70%
  * Citrobacter freundii*      85                                        1    1.02%    19    19.39%
  * Klebsiella oxytoca*        133                                       2    1.31%    4     2.61%
  * Enterobacter* other        24                                        3    10.34%   5     17.24%
  * Citrobacter* other         52                                        0    0.00%    8     12.50%
  * Serratia* other            5                                         0    0.00%    1     14.29%
  * Klebsiella* other          9                                         0    0.00%    0     0.00%
  * Pseudomonas aeruginosa*    331                                       31   7.60%    30    7.35%
  * Acinetobacter baumannii*   12                                        3    21.43%   3     21.43%
  * *Other                     94                                        3    2.40%    13    10.40%
                               Patients With a GP Isolate (n = 1782)                         
                               GP Isolates (n = 2333)                                        
  *Enterococcus* spp.          1072                                           45.95%         
  * Enterococcus faecalis*     431                                            18.47%         
  * Enterococcus faecium*      354                                            15.17%         
  *Staphylococcus aureus*      241                                            10.33%         
  * *MRSA                      83                                             3.56%          
  *Bacteroides* spp.           152                                            6.52%          
                               Patients With a Polymicrobial Infection                       
  Polymicrobial                1512                                           33.95%         
  * *2 organisms               1118                                           25.11%         
  * *3 or more organisms       394                                            8.85%          

Abbreviations: C3R, resistant to third-generation cephalosporin; cIAI, complicated intra-abdominal infection; CR, carbapenem-resistant; GN, gram-negative; GP, gram-positive.

^a^Denominators for percentages are as follows: all GN isolates for GN; all GP isolates for GP; overall cohort (n = 4453) for polymicrobial infections.

Approximately one-quarter (n = 1185) of all patients received antimicrobial regimens that included ECT. Patients on ECT did not differ from those on non-ECT with regard to age, gender distribution, or race ([Table 2](#T2){ref-type="table"}). Compared with those on non-ECT, patients on ECT were less likely to be admitted from home (82.5% vs 86.0%) and more likely to be admitted from a non--acute care facility (6.4% vs 5.0%), but also less likely to be admitted emergently (76.0% vs 81.4%; *P* \< .05 for each) ([Table 2](#T2){ref-type="table"}). Additionally, ECT (1.8 ± 2.2) patients had a higher mean Charlson comorbidity score than non-ECT (1.6 ± 2.1) patients. ECT was more likely to be given in hospitals in the South in medium-sized (200--399 beds), nonacademic, and urban institutions than non-ECT. Similarly, by all measures of severity of acute illness, those in the ECT group were sicker than those in the non-ECT group ([Table 2](#T2){ref-type="table"}).

###### 

Demographic, Clinical, and Hospital Characteristics Present at Hospital Admission Among Patients With ≥1 Gram-Negative Organism

                                                          ECT, No.      ECT, %    Non-ECT, No.   Non-ECT, %   *P*
  ------------------------------------------------------- ------------- --------- -------------- ------------ --------
  Mean age (SD), y                                        61.1 (17.0)             61.0 (17.0)                 .910
  Gender: male                                            617           52.07%    1765           54.01%       .251
  Race                                                                                                        
  * *White                                                910           76.79%    2435           74.51%       .439
  * *Black                                                114           9.62%     331            10.13%       
  * *Hispanic/other                                       150           12.66%    470            14.38%       
  * *Unknown                                              11            0.93%     32             0.98%        
  Admission source                                                                                            
  * *Home                                                 978           82.53%    2810           85.99%       .014
  * *Clinic                                               94            7.93%     247            7.56%        
  Transfer from another non--acute health care facility   76            6.42%     150            4.59%        
  * *Other                                                37            3.12%     59             1.80%        
  Admission type                                                                                              
  * *Emergency                                            900           75.95%    2659           81.36%       
  * *Urgent                                               120           10.13%    237            7.25%        
  * *Elective                                             155           10.95%    358            10.95%       \<.001
  * *Trauma                                               4             0.34%     9              0.28%        
  * *Unknown                                              6             0.51%     5              0.15%        
  Elixhauser comorbidities                                                                                    
  * *Congestive heart failure                             158           13.33%    397            12.15%       .290
  * *Valvular disease                                     64            5.40%     170            5.20%        .793
  * *Pulmonary circulation disease                        34            2.87%     76             2.33%        .302
  * *Peripheral vascular disease                          112           9.45%     254            7.77%        .071
  * *Paralysis                                            24            2.03%     77             2.36%        .512
  * *Other neurological disorders                         95            8.02%     228            6.98%        .237
  * *Chronic pulmonary disease                            240           20.25%    614            18.79%       .273
  * *Diabetes without chronic complications               191           16.12%    535            16.37%       .840
  * *Diabetes with chronic complications                  98            8.27%     286            8.75%        .613
  * *Hypothyroidism                                       154           13.00%    379            11.60%       .204
  * *Renal failure                                        188           15.86%    469            14.35%       .208
  * *Liver disease                                        73            6.16%     211            6.46%        .721
  * *Peptic ulcer disease with bleeding                   31            2.62%     59             1.81%        .089
  * *AIDS                                                 6             0.51%     4              0.12%        .027
  * *Lymphoma                                             16            1.35%     28             0.86%        .141
  * *Metastatic cancer                                    62            5.23%     149            4.56%        .350
  * *Solid tumor without metastasis                       67            5.65%     156            4.77%        .234
  * *Rheumatoid arthritis/collagen vascular               33            2.78%     104            3.18%        .497
  * *Coagulopathy                                         187           15.78%    349            10.68%       \<.001
  * *Obesity                                              245           20.68%    677            20.72%       .976
  * *Weight loss                                          325           27.43%    630            19.28%       \<.001
  * *Fluid and electrolyte disorders                      661           55.78%    1537           47.03%       \<.001
  * *Chronic blood loss anemia                            40            3.38%     63             1.93%        .005
  * *Deficiency anemia                                    309           26.08%    721            22.06%       .005
  * *Alcohol abuse                                        58            4.89%     163            4.99%        .899
  * *Drug abuse                                           26            2.19%     88             2.69%        .352
  * *Psychosis                                            91            7.68%     190            5.81%        .024
  * *Depression                                           154           13.00%    356            10.89%       .052
  * *Hypertension                                         623           52.57%    1715           52.48%       .955
  Charlson comoribidity score                                                                                 
  * *0                                                    469           39.58%    1406           43.02%       .097
  * *1                                                    884           18.82%    661            20.23%       
  * *2                                                    169           14.26%    415            12.70%       
  * *3                                                    97            8.19%     253            7.74%        
  * *4                                                    72            6.08%     166            5.08%        
  * *5+                                                   155           13.08%    367            11.23%       
  * *Mean (SD)                                            1.8 (2.2)               1.6 (2.1)                   .011
  * *Median \[IQR\]                                       1 \[0--3\]              1 \[0--2\]                  .006
  Hospital characteristics                                                                                    
  * *Census region                                                                                            
  * *Midwest                                              342           28.86%    941            28.79%       \<.001
  * *Northeast                                            137           11.56%    525            16.06%       
  * *South                                                558           47.09%    1204           36.84%       
  * *West                                                 148           12.49%    598            18.30%       
  * *No. of beds                                                                                              
  * *\<100                                                36            3.04%     142            4.35%        
  * *100--199                                             141           11.90%    376            11.51%       \<.001
  * *200--299                                             318           26..84%   686            20.99%       
  * *300--399                                             200           16.88%    451            13.80%       
  * *400--499                                             145           12.24%    571            17.47%       
  * *500+                                                 345           29.11%    1042           31.88%       
  * *Teaching                                             501           42.28%    1532           46.88%       .006
  * *Urban                                                1042          87.93%    2738           83.78%       .001

Abbreviations: ECF, extended care facility; ECT, empiric carbapenem treatment; IQR, interquartile range.

There were limited differences in organism distribution between the ECT and non-ECT groups ([Table 3](#T3){ref-type="table"}). *E. coli* were less likely, whereas *P. aeruginosa* and *Enterococcus* spp. were more likely to be isolated in the ECT group. Notably, both C3R (10.1% vs 5.1%; *P* \< .001) and CR (3.6% vs 1.2%; *P* \< .001) infections were more frequent in the ECT than in the non-ECT group. In other words, although a presumptive ESBL pathogen was observed more often in those prescribed ECT, the actual prevalence of ESBL organisms was low even among those treated with a carbapenem. On average, compared with those treated with non-ECT, patients on ECT developed their cIAI later in the hospitalization (5.5 ± 11.8 vs 3.2 ± 5.2 days; *P* \< .001) and were more likely to have their infections classified as HCA or HO than CA ([Table 3](#T3){ref-type="table"}). Of the individual and combination regimens commonly used in cIAI, ertapenem was the most common in the ECT group (57.1%), and meropenem was the second most common (39.3%). In the non-ECT group, piperacillin-tazobactam was used in nearly three-quarters of all patients (72.6%). Among patients for whom appropriateness of the empiric regimen could be determined, there was no difference in exposure to IET between the ECT and non-ECT groups ([Table 3](#T3){ref-type="table"}).

###### 

Infection and Treatment Characteristics Among Patients With ≥1 Gram-Negative Organism

                                                                                  ECT, No.     ECT, %   Non-ECT, No.   Non-ECT, %   *P*
  ------------------------------------------------------------------------------- ------------ -------- -------------- ------------ -----------
  Culture source                                                                                                                    
  * *Abdominal only                                                               383          32.32%   1303           39.87%       
  * *Both                                                                         646          54.51%   1576           48.23%       \<.001
  * *Blood only                                                                   156          13.16%   389            11.90%       
  Organisms                                                                                                                         
  * *Gram-negative isolates                                                                                                         
  *  Klebsiella pneumoniae*                                                       195          16.46%   579            17.72%       .326
  *  Proteus mirabilis*                                                           33           2.78%    84             2.57%        .693
  *  Escherichia coli*                                                            641          54.09%   1983           60.68%       \<.001
  *  Enterobacter cloacae*                                                        58           4.89%    169            5.17%        .711
  *  Providencia* spp.                                                            2            0.17%    8              0.24%        1.000
  *  Serratia marcescens*                                                         5            0.42%    19             0.58%        .521
  *  Morganella morganii*                                                         12           1.01%    32             0.98%        .921
  *  Enterobacter aerogenes*                                                      14           1.18%    46             1.41%        .563
  *  Proteus* spp.                                                                5            0.42%    18             0.55%        .596
  *  Citrobacter freundii*                                                        29           2.45%    69             2.11%        .500
  *  Klebsiella oxytoca*                                                          41           3.46%    112            3.43%        .958
  *  Enterobacter* other                                                          8            0.68%    21             0.64%        .905
  *  Citrobacter* other                                                           13           1.10%    51             1.56%        .251
  *  Serratia* other                                                              3            0.25%    4              0.12%        .392
  *  Klebsiella* other                                                            5            0.42%    4              0.12%        .062
  *  Pseudomonas aeruginosa*                                                      130          10.97%   278            8.51%        .012
  *  Âcinetobacter baumannii*                                                     6            0.51%    8              0.24%        .168
  *  Stenotrophomonas maltophilia*                                                2            0.17%    8              0.24%        1.000
  *  *Other                                                                       22           1.86%    103            3.15%        .021
  *  *CR                                                                          43           3.63%    41             1.25%        \<.001
  *  *C3R                                                                         120          10.13%   168            5.14%        \<.001
  * *Gram positive isolates                                                                                                         
  *  Enterococcus* spp.                                                           346          29.20%   726            22.22%       \<.001
  *  Staphylococcus aureus*                                                       65           5.49%    176            5.39%        .897
  *  Bacteroides* spp.                                                            39           3.29%    113            3.46%        .787
  *  Candida* spp.                                                                41           3.46%    98             3.00%        .434
  Infection characteristics                                                                                                         
  * *Monomicrobial                                                                772          66.15%   2169           66.37%       .774
  * *Polymicrobial                                                                                                                  
  * *2 organisms                                                                  308          25.99%   810            24.79%       
  * *3 or more organisms                                                          105          8.86%    289            8.84%        
  * *Gram-negative only                                                           669          56.46%   2002           61.26%       
  * *Both gram-negative and gram-positive                                         306          25.82%   794            24.30%       .006
  * *Gram-positive only                                                           210          17.72%   472            14.44%       
  * *Community-onset cIAI                                                         1028         86.75%   2976           91.06%       
  *  *Community-acquired                                                          682          57.55%   2116           64.75%       \<.001
  *  *Health care--associated                                                     346          29.20%   860            26.32%       
  * *Hospital-onset cIAI                                                          157          13.25%   292            8.94%        
  * *Time to cIAI                                                                                                                   
  *  *Mean (SD)                                                                   5.5 (11.8)            3.2 (5.2)                   \<.001
  *  *Median \[IQR\]                                                              2 \[1--6\]            2 \[1--3\]                  \<.001
  Antibiotics within 90 d before admission                                        199          16.79%   414            12.67%       \<.001
  Antibiotics during index hospitalization before cIAI onset                      672          56.71%   1738           53.18%       .037
  CR organism within 90 d before admission                                        3            0.25%    4              0.12%        .392
  C3R organism within 90 d before admission                                       11           0.93%    12             0.37%        .032
  Illness severity measures at cIAI onset (by day 2 from index infection onset)                                                     
  * *ICU admission                                                                635          53.59%   1167           35.71%       \<.001
  * *Mechanical ventilation                                                       517          43.63%   913            27.94%       \<.001
  * *Vasopressors                                                                 510          43.04%   1076           32.93%       \<.001
  * *Dialysis                                                                     82           6.92%    134            4.10%        \<.001
  * *Severe sepsis                                                                287          24.22%   520            15.91%       \<.001
  *  *Severe sepsis present on admission                                          168          14.18%   326            9.98%        \<.001
  * *Septic shock                                                                 333          28.10%   576            17.63%       \<.001
  *  *Septic shock present on admission                                           179          15.11%   367            11.23%       \<.001
  Empiric cIAI treatment regimens (by day 2 from index infection onset)                                                             
  * *Cefoxitin                                                                    97           8.19%    350            10.71%       .013
  * *Ertapenem                                                                    677          57.13%   0              0.00%        \<.001/NA
  * *Moxifloxacin                                                                 3            0.25%    8              0.24%        1.000
  * *Ciprofloxacin                                                                113          9.54%    502            15.36%       \<.001
  * *Levofloxacin                                                                 96           8.10%    358            10.95%       .005
  * *Ampicillin-sulbactam                                                         41           3.46%    261            7.99%        \<.001
  * *Moxifloxacin + metronidazole                                                 2            0.17%    4              0.12%        .660
  * *Ciprofloxacin + metronidazole                                                84           7.09%    399            12.21%       \<.001
  * *Levofloxacin + metronidazole                                                 62           5.23%    254            7.77%        .004
  * *Cefazolin + metronidazole                                                    32           2.70%    260            7.96%        \<.001
  * *Cefuroxime + metronidazole                                                   1            0.08%    0              0.00%        .266
  * *Ceftriaxone + metronidazole                                                  34           2.87%    23             7.19%        \<.001
  * *Cefotaxime + metronidazole                                                   0            0.00%    3              0.09%        .570
  * *Imipenem-cilastatin                                                          85           7.17%    0              0.00%        \<.001/NA
  * *Meropenem                                                                    466          39.32%   0              0.00%        \<.001/NA
  * *Doripenem                                                                    24           2.03%    0              0.00%        \<.001/NA
  * *Piperacillin-tazobactam                                                      383          32.32%   2371           72.55%       \<.001
  * *Tigecycline                                                                  17           1.43%    24             0.73%        .031
  * *Ticarcillin-clavulanic acid                                                  0            0.00%    0              0.00%        1.000
  * *Cefepime                                                                     51           4.30%    241            7.37%        \<.001
  * *Ceftazidime                                                                  2            0.17%    16             0.49%        .183
  * *Ceftolozane-tazobactam                                                       0            0.00%    0              0.00%        1.000
  * *Ceftazidime-avibactam                                                        0            0.00%    1              0.03%        1.000
  Empiric treatment appropriateness                                                                                                 
  * *Non-IET                                                                      781          65.91%   2442           74.72%       \<.001
  * *IET                                                                          77           6.50%    220            6.73%        
  * *Indeterminate                                                                327          27.59%   606            18.54%       

Abbreviations: cIAI, complicated intra-abdominal infection; C3R, resistant to third-generation cephalosporin; CR, carbapenem-resistant; ECT, empiric carbpenem treatment; ICU, intensive care unit; IET, inappropriate empiric therapy; IQR, interquartile range.

All the examined unadjusted outcomes were worse in the group on ECT than non-ECT ([Table 4](#T4){ref-type="table"}). Adjusting for confounders known at the onset of cIAI, including demographics, hospital characteristics, and chronic and acute illness markers, worsening of some, though not all, of the outcomes persisted in association with receiving ECT ([Table 5](#T5){ref-type="table"}). Though hospital mortality, 30-day readmission, and AKI/AKI-D incidence were not increased in the ECT group compared with non-ECT, and though ECT was associated with significant independent excess in the total hospital LOS (0.96 days; 95% confidence interval \[CI\], 0.29 to 1.64), total hospital costs (\$3897; 95% CI, \$2001 to \$5792), postinfection costs (\$3844; 95% CI, \$1921 to \$5767), and in the risk of HO-CDI (odds ratio \[OR\], 2.14; 95% CI, 1.02 to 4.47), clinical deterioration (OR, 1.26; 95% CI, 1.04 to 1.52), and treatment failure (subhazard ratio, 1.62; 95% CI, 1.41 to 1.86), the postinfection LOS in the ECT group was shorter than in the non-ECT group (--0.61 days; 95% CI, --1.18 to --0.04).

###### 

Unadjusted Hospitalization Outcomes Among Patients With ≥1 Gram-Negative Organism

                                     ECT                         \%       Non-ECT                     \%       *P*
  ---------------------------------- --------------------------- -------- --------------------------- -------- --------
  Hospital mortality                 124                         10.46%   213                         6.52%    \<.001
  30-d readmission                   144                         13.57%   316                         10.34%   .004
  Hospital costs total, \$                                                                                     
  * *Mean (SD)                       56 406 (91 778)                      36 289 (50 414)                      \<.001
  * *Median \[IQR\]                  27 638 \[14 495--61 440\]            19 616 \[11 373--39 361\]            \<.001
  Postinfection hospital costs, \$                                                                             
  * *Mean (SD)                       34 365 (61 421)                      22 803 (41 127)                      \<.001
  * *Median \[IQR\]                  13 927 \[5998--36 348\]              9070 \[3866--23 904\]                \<.001
  Postinfection LOS, d                                                                                         
  * *Mean (SD)                       13.2 (19.4)                          9.4 (13.7)                           \<.001
  * *Median \[IQR\]                  8 \[4--15\]                          6 \[3--11\]                          \<.001
  Exploratory outcomes                                                                                         
  HO-CDI                             14                          1.18%    16                          0.49%    .013
  * *AKI                             414                         34.94%   904                         27.66%   \<.001
  *  *Incident AKI                   173                         14.60%   361                         11.05%   .001
  *  *AKI POA                        240                         20.25%   549                         16.80%   .008
  AKI-D                              33                          2.78%    55                          1.68%    .020
  * *Incident AKI-D                  19                          1.60%    27                          0.83%    .023
  * *AKI-D POA                       4                           0.37%    12                          0.34%    .884
  Clinical deterioration             548                         46.24%   1292                        39.53%   \<.001
  Treatment failure                  510                         43.04%   1029                        31.49%   \<.001

Abbreviations: AKI, acute kidney injury; AKI-D, AKI with dialysis; CDI, *Clostridioides difficile* infection; ECT, empiric carbapenem treatment; HO, hospital onset; IQR, interquartile range; LOS, length of stay; POA, present on admission.

###### 

Adjusted Association of ECT With Outcomes

  Outcome                                  Measure           Point Estimate   95% Confidence Interval   *P*
  ---------------------------------------- ----------------- ---------------- ------------------------- --------
  Mortality                                Odds ratio        1.11             0.83 to 1.48              .502
  30-d readmission                         Odds ratio        1.18             0.93 to 1.49              .167
  Hospital costs (all)                     Excess \$         3897             2001 to 5792              \<.001
  Hospital costs (post--infection onset)   Excess \$         3844             1921 to 5767              \<.001
  Total LOS                                Excess days       0.96             0.29 to 1.64              .005
  Post--infection onset LOS                Excess days       --0.59           --1.15 to --0.03          .039
  Exploratory                                                                                           
  HO-CDI                                   Odds ratio        2.15             1.02 to 4.50              .044
  AKI                                      Odds ratio        1.09             0.90 to 1.32              .389
  Incident AKI                             Odds ratio        1.07             0.85 to 1.34              .588
  AKI-D                                    Odds ratio        1.39             0.88 to 2.21              .163
  Incident AKI-D                           Odds ratio        1.55             0.84 to 2.87              .162
  Clinical deterioration                   Odds ratio        1.26             1.04 to 1.52              .017
  Treatment failure                        Subhazard ratio   1.28             1.14 to 1.45              \<.001

Abbreviations: AKI, acute kidney injury; AKI-D, AKI with dialysis; CDI, *Clostridioides difficile* infection; ECT, empiric carbapenem treatment; HO, hospital onset; LOS, length of stay.

In contrast, the postinfection LOS in the ECT group was statistically similar to the non-ECT group. Sensitivity analyses produced similar results ([Supplementary Data](#sup11){ref-type="supplementary-material"}). We did observe a modest excess in postinfection LOS in the ECT group relative to the non-ECT group (0.25 days; 95% CI, 0.03 to 0.48).

DISCUSSION {#s10}
==========

We demonstrate that among hospitalized patients with cIAI, only a small minority (1.4%) had a positive culture. The use of ECT, employed in over one-quarter of all patients, exceeded the prevalence of C3R by a factor of 3. Importantly, the organisms with the highest prevalence of C3R, where carbapenems may represent the treatment of choice (*Enterobacter* spp., *A. baumannii*), were an order of magnitude less common as causes of cIAI than those with the lowest rates of resistance (*E. coli*, *K. pneumoniae*). Despite this, the most common C3R pathogen was *E. coli*, accounting for nearly half of all C3R organisms. Importantly, although hospital mortality and 30-day readmission rates in the 2 groups were similar, ECT was associated with a reduction in the postinfection LOS. Higher postinfection costs were associated with ECT despite a modest reduction in postinfection LOS.

The dissociation between costs and LOS may be due to several factors. One possibility is that the higher raw mortality in the ECT group implies greater resource utilization without extension of life. Another potential explanation is a statistical anomaly known as Simpson's paradox. This arises essentially because of potentially heterogeneous groups combined into a single mean value, as well as the presence of residual confounding. It would be useful to examine this issue in future research.

The discordance between the total and postinfection LOS between the 2 groups suggests that the overall prolongation of LOS in the ECT group occurred largely in the pre-infection period, possibly pointing to, along with prior exposure to antimicrobials and history of C3R, an increased probability of a resistant organism. In this way, LOS is a marker for ECT use, rather than its consequence. ECT was also linked with an increase in the risk of developing HO-CDI, as well as of clinical deterioration, and treatment failure relative to other empiric treatments, even after adjusting for many confounders known at cIAI onset. Together, these findings, along with the stably low prevalence of CR, suggest that opportunities exist for carbapenem-sparing strategies in cIAI. Shifting away from ECT in cIAI, therefore, could potentially reduce selection pressure for carbapenem resistance and limit rates of important, publicly reported complications such as CDI.

Carbapenems have been increasingly relied upon in cIAI for many years. However, the Surgical Infections Society (SIS) in 2017 updated its evidence-based guidelines for the treatment of cIAI \[[@CIT0028]\]. At that time, the SIS indicated that carbapenems were not recommended as routine empiric agents. Carbapenems, though, were noted to serve a role in select "higher-risk" patients, namely those at risk for a resistant pathogen (HCA and HO cIAI) or those who exhibit severe signs of acute decompensation, such as the need for vasopressors and/or mechanical ventilation. Our data suggest that, on one level, practitioners appear to heed this advice. Specifically, we saw that ECT was administered more frequently than non-ECT to HCA- and HO-cIAI patients. We further observed that all markers of acute illness severity were higher in patients in the ECT group than those in the non-ECT group, thus comporting with the recommendations. Nonetheless, the majority of patients with ECT suffered from a CO-cIAI.

We further note that in the group receiving ECT, approximately one-third of the patients also received empiric piperacillin-tazobactam. This likely represents a switch during the transfer of care between teams in the emergency department, the ward, the operating room, and/or the ICU. Moreover, nearly three-quarters received piperacillin-tazobactam in the non-ECT group, despite the fact that the SIS guidelines also recommend reserving this drug for high-risk patients.

In part, the use of either of these broad agents reflects limitations in rapid diagnostic technologies that might help to alleviate uncertainty about initial empiric therapy. Although bedside rapid molecular testing is on the horizon, until it is widely available, appreciating local antibiograms and the interaction of the hospital's microbiology with the specific syndrome in question will remain critical for limiting the use of broad-spectrum coverage. Furthermore, predictive models, if validated, may prove a useful adjunct to stratifying the risk for resistance \[[@CIT0029], [@CIT0030]\].

The hospital mortality rate in our cohort did not differ from that reported by other authors, supporting the generalizability and face validity of our results. For example, Solomkin and coworkers examined the outcomes of cIAI treatment with tigecycline in a group of patients conducted using the Premier database between 2009 and 2012 \[[@CIT0031]\]. In propensity score--matched groups, hospital mortality was between 10.2% and 11.1%, or similar to what we observed in the ECT group. One major difference between Solomkin's study and ours is that we required patients to have a positive abdominal or blood culture, thus possibly selecting for sicker patients. In view of this, it is encouraging that we did not detect higher death rates in our cohort.

Our study builds on prior work and adds to the body of knowledge on the outcomes of cIAI in other ways. Although adjusting for factors present at the onset of cIAI eliminated differences in mortality and 30-day readmission, ECT was associated with greater total hospital LOS but a reduction in the postinfection LOS. At the same time, we estimated added postinfection costs of \~\$3800. These observations with regard to the potential implications of ECT for resource use are novel and suggest that clinicians rightly target ECT to patients who have spent a longer time in the hospital and are more acutely ill, thus raising their risk for a resistant infection. We also examined novel yet important outcomes such as the risk of incident *C. difficile* and other complications that impact hospital course.

Though rare in both groups, CDI was strongly associated with ECT, occurring at more than double the rate seen with other regimens. This nexus between ECT and CDI is worrisome and may reflect the important impact of carbapenems on gastrointestinal flora. This finding contrasts with that of Metzger et al., who in a single-center cohort failed to find a connection in cIAI between CDI and any specific antimicrobial class \[[@CIT0032]\]. This relationship requires further examination in future research.

Incident AKI, on the other hand, is somewhat more likely in ECT patients. Notably, the AKI prevalence in our cohort was high, with approximately one-third of all patients suffering this outcome. This is considerably higher than what has been described in other studies, though it is not inconsistent with the high degree of acute illness (vasopressor use in one-third of the population) \[[@CIT0026]\]. Given that AKI, and particularly AKI-D, is an important determinant of hospital costs and mortality, future studies need to examine potential modifiable risk factors for developing AKI in cIAI patients.

Two additional important end points are worth highlighting: the incidence of clinical deterioration and treatment failure. Though their frequency in our study is lower than in that by Solomkin et al., this is most likely due to a different population (theirs did not require a positive culture) and different definitions for these events \[[@CIT0031]\]. Nevertheless, both are common in both groups.

Our study has a number of limitations. As a retrospective cohort study, it is susceptible to various types of bias, most notably selection bias. We attempted to minimize this by defining enrollment criteria prospectively, as well as by enrolling consecutive patients who met the selection criteria. Confounding is another threat to the validity of an observational study, particularly when evaluating treatment effectiveness. Similarly, in the case of any treatment exploration, there is also a possibility specifically of confounding by indication, where broader-spectrum treatment may be a marker of more severe disease. Though we adjusted for illness severity among many other covariates, residual confounding may still be present. For example, we lacked access to information regarding source control, an important determinant of outcomes in cIAI. This implies that the outcome estimates may not be wholly attributable to ECT. However, we minimized residual confounding by using severity of illness variables known at cIAI onset. We also did not stratify by infection source in this analysis. We omitted this, as the recent SIS guideline does not recommend including this as a determinant of risk \[[@CIT0028]\]. Despite these shortcomings, our results may point to potential carbapenem overuse as an empiric regimen.

Misclassification is a possibility as well, particularly given that we relied on administrative coding to identify the cohort and some of the outcomes. We tried to minimize it by (a) using previously published algorithms and (b) erring on the side of specificity at the expense of sensitivity \[[@CIT0018], [@CIT0022], [@CIT0026], [@CIT0033]\]. Furthermore, when present, such misclassification would affect both groups equally, thus reducing any actual differences between the groups. Because we used a large multicenter database for our analyses, lack of generalizability is not a major concern. However, given that our cohort includes only culture-positive cIAI patients, the results may not generalize broadly to those cIAI patients who either were not sampled for a pathogen or did not grow one out.

In summary, we show that the prevalence rates of C3R, a surrogate for ESBL, and CR in culture-positive patients with cIAI are still relatively low in the United States. Nevertheless, ECT is used in one-quarter of all cIAI patients, with some associated adverse outcomes, including an increase in the risk of CDI, clinical deterioration, treatment failure, and excess costs. Although it remains difficult to attribute some of these end points specifically to carbapenem use rather than to other underlying factors not captured in the data, these are important associations that future studies should attempt to disentangle. In a broad sense, our findings point to potential opportunities for antimicrobial stewardship programs as a compliment to the care of cIAI patients, so as to address the appropriate use of broad-spectrum therapies.

Supplementary Data {#s11}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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